Part 1 of a 6-Part Series
|
|
- Duane Wright
- 8 years ago
- Views:
Transcription
1 Release Date: April 1, Termination Date: April 1, Estimated time to complete this 6-part newsletter series: 3.0 hours. For additional updates, go to Awake and Involved: Addressing Excessive Daytime Sleepiness in Patients with Parkinson s Disease Part 1 of 6: Overview of Parkinson s Disease Dear Colleague: Sleep dysfunction, although common in the elderly, is more frequent and more severe in patients with Parkinson s disease (PD). Almost all patients with PD have disrupted sleep and almost half are excessively sleepy during the daytime. Sleep dysfunction harms patients and their caregivers by interfering with social interactions, work performance, driving, independence, psychological well-being, and tolerance to antiparkinsonian medications. The aims of this series of six Treatment Reporters are twofold: to help neurologists understand the complex etiology of sleep problems and excessive daytime sleepiness (EDS) in patients with PD and to offer treatment options. This issue begins with an overview of PD. With the help of a panel of specialists in Parkinson s disease and sleep, we will go on to cover such topics as clinical assessment of the PD patient for sleep problems and risk factors that predispose PD patients to sleep disorders. We will review the complex differential diagnosis of EDS, focusing on sleep disturbances, medications, and pathophysiology. We will then present therapeutic strategies for managing these problems, including sleep hygiene recommendations, treatment of sleep disorders, adjustment of current medications, and the use of agents designed to promote wakefulness. Sincerely, Charles H. Adler, MD, PhD Professor of Neurology Chair, Mayo Clinic Division of Movement Disorders Mayo Clinic Scottsdale Scottsdale, Arizona Introduction Parkinson s disease (PD) is estimated to affect 1 million Americans, with about 60,000 new cases diagnosed each year. 1 The prevalence of PD is expected to increase in the next decades as the baby boomer population ages. Specific causes of PD have not been identified, but advanced age, male sex, family history, and environmental toxins are known risk factors. Parkinson s disease may display either autosomal dominant or recessive Michael J. Thorpy, MD Director Sleep-Wake Disorder Center Montefiore Medical Center Bronx, New York inheritance. Studies in twins suggest that genetics may be a factor in young-onset PD, while the environment may play a more significant role in older-onset PD. These factors may result in PD by enhancing excessive accumulation of intracellular protein and extracellular protein aggregates, resulting in cell death. 1,2 Pathology Selective neuronal cell death results in depigmentation of the substantia nigra as well as depletion of dopamine in the striatum, especially in the dorsal and Part 1 of a 6-Part Series Watch Your Mail for the Next Issue! Learning Objectives This activity has been designed for neurologists who treat patients with Parkinson s disease. After completing these activities, the physician should be able to: Describe the burden of illness that excessive daytime sleepiness imposes on patients with PD. Recognize the possible etiologies of excessive daytime sleepiness in patients with PD. Employ effective measures to assess sleepiness to inform clinical decision making Examine pharmacotherapies aimed at reducing excessive daytime sleepiness in patients with PD. Incorporate new approaches to the management of excessive daytime sleepiness in PD patients to maximize quality of life and patient satisfaction. CME Information Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This 6-part newsletter is planned and produced as an independent CME activity in accordance with the ACCME Essential Areas and Policies. Projects In Knowledge designates this educational activity for a maximum of 3.0 Category 1 credits toward the AMA Physician s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity. Successful completion for 3.0 hours of CME credit requires a passing score of 70% or higher on the posttest. Full instructions for submission are included on the posttest accompanying this CME newsletter. Disclosure The Disclosure Policy of Projects In Knowledge requires that the faculty participating in a CME activity disclose to the audience any significant relationship they may have with a pharmaceutical or medical equipment company, product, or service that may be mentioned as part of their presentation, as well as any relationship with the commercial supporter of this activity. Charles H. Adler, MD, PhD, has received grant/research support from Cephalon, Inc, Elan Pharmaceuticals, GlaxoSmithKline, Pharmacia & Upjohn, and Teva Pharmaceuticals USA; and is a consultant for Elan Pharmaceuticals, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, and Pharmacia & Upjohn. Michael J. Thorpy, MD, is on the speakers bureau of Cephalon, Inc, Orphan Medical Inc, and Sanofi- Synthelabo. The opinions expressed during this 6-part activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge or the commercial supporter. This activity may include a discussion of therapies that are unapproved for use or investigational, ongoing research, or preliminary data. This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the prerogative of the physician caring for the patient. This independent CME activity is supported by an educational grant from Cephalon, Inc. Copyright 2003, Projects In Knowledge, Inc. Secaucus, NJ All rights reserved. Download this 6-part series Awake and Involved: Addressing Excessive Daytime Sleepiness in Patients with Parkinson s Disease available at
2 REPORTER SM : NEUROLOGY intermediate putamen. The Lewy body, an intracytoplasmic eosinophilic inclusion in the pigmented nuclei of the brain stem, is the pathologic hallmark of PD. Neuropathologic changes can also be seen in the locus ceruleus and cerebral cortex. Since there are no diagnostic tests that are definitive for PD, a final diagnosis can only be made by autopsy. Motor Features The diagnosis of PD continues to be based on signs and symptoms, requiring at least two of three cardinal signs: resting tremor, bradykinesia, and rigidity. A fourth cardinal sign, postural instability, usually develops later in the illness. 3,4 Tremor, the most obvious symptom of PD, is usually asymmetric and exacerbated by stress and fatigue. Bradykinesia is often the most troubling symptom, slowing the patient in many activities of daily living. Other symptoms include hypophonia, micrographia, drooling, masked facies, difficulty with dressing, bathing, and feeding, reduced arm swing, flexed posture, and shuffling gait. At first, the subtlety of these signs and similarity to features of normal aging can make the diagnosis of early disease more difficult. Rigidity of passive joint movement is characteristic of PD and is mainly a cogwheel rigidity (ratchet-like movement). Symptoms generally change and worsen over time. Non-motor Features For many patients, the non-motor features of PD can be even more disabling than their motor problems. 1 Depression, psychosis, pain, and cognitive impairment can greatly interfere with independence, activities of daily living, and quality of life. More than 90% of patients with PD experience autonomic symptoms, such as paroxysmal sweating, orthostatic hypotension, constipation, bladder retention, nocturia, impotence, and hypothermia. Sleep/wake alterations affect almost all patients and are particularly disruptive to patients coping with PD, as will be described in the next Treatment Reporter. Differential Diagnosis The differential diagnosis of PD encompasses a variety of neurodegenerative and metabolic conditions (Table 1). 5 Parkinsonism refers to a set of clinical signs and symptoms that are typical of PD, but can be due to other causes, which must be ruled out before making a diagnosis of idiopathic PD. Parkinson s disease tremor of the hands can be distinguished from essential tremor because it occurs predominantly at rest and may also affect the jaws and legs, while essential tremor of the hands occurs more with action and often affects the voice and head/neck. Although arm tremor and mild cogwheel rigidity can be seen in both disorders, bradykinesia is usually a sign of PD. Drug-induced parkinsonism is one of the most critical to consider in the differential diagnosis, because it is iatrogenic and can be treated by withdrawal of the offending medication. Clues to drug-induced parkinsonism include: 1) subacute symptoms with bilateral onset, and rapid progression; 2) early postural tremor; and 3) concurrent choreo-athetoid dyskinesias, especially of the face and mouth. 5 Medications that can cause parkinsonism include antipsychotic agents, combination antidepressant/antipsychotics, anti-emetics, and dopaminedepleting drugs. Dementia and parkinsonism frequently coexist and may present either simultaneously or in sequence. Disorders, such as dementia with Lewy bodies, corticobasal degeneration, or vascular parkinsonism may present with early onset of dementia. 3,5 In PD, memory loss and other cognitive difficulties are a relatively DAs minor late-onset component in contrast to AD. Rigidity, bradykinesia, and gait disorders have been described in up to 50% of AD patients. Without reliable biologic markers, idiopathic PD may be misdiagnosed. Even at noted PD centers, only about 80% of parkinsonism cases are correctly diagnosed with idiopathic PD during life. 6 The best predictors of a pathologic diagnosis of PD include unilateral onset of symptoms, including rest tremor, and either bradykinesia or rigidity, as well as a good initial response to levodopa. Computed tomography or MRI do not reveal any specific changes related to PD, although they can rule out conditions that require different management. 3 Treatment Options Pharmacotherapy Algorithms have been developed to aid in the diagnosis and treatment of PD (Fig. 1). 1,3,7 Pharmacotherapy for PD should be individualized and the dose titrated to maximize the therapeutic response while minimizing side effects. Treatment response is also an essential component of the long-term management of PD, as adjunctive therapy or combination therapy may be required. Nonpharmacologic interventions, including education, exercise, nutrition, and support, should also be provided. Deciding when to start pharmacotherapy may reflect a clinician s preferences. Some advocate early treatment to Nonpharmacologic treatment Addition drugs Anticholinergics Amantadine Combination therapy L-DOPA COMT inhibitors Parkinson s Disease Mild Disability Pharmacologic Treatment Functional impairment Yes Marked disability Drug modification to improve efficacy and reduce side effects No Surgery Figure 1. Management of Parkinson s disease. With permission of Lippincott Williams and Wilkins. 2
3 TREATMENT REPORTER Awake and Involved: Addressing Excessive Daytime Sleepiness in Patients with Parkinson s Disease provide patients with early maximal clinical benefit while others prefer to delay treatment to minimize the risk of developing long-term motor complications. Most agree that the decision when to start pharmacotherapy usually coincides with the onset of functional impairment as defined for each patient. 1 For patients with functional impairment, levodopa or dopaminergic agonists (DAs) are recommended for initial pharmacotherapy. Combining levodopa with a DA is recommended by some specialists. Anticholinergic medications Anticholinergic agents (eg, trihexyphenidyl, benztropine) are infrequently used because of cognitive muscarinic side effects and limited efficacy. 1,8 However, younger patients with early PD may derive some benefit. Anticholinergic therapy in older patients, especially those with cognitive dysfunction, is not recommended. Amantadine Because its antiparkinsonian benefits are limited, amantadine may be used for patients with early PD as it has mild symptomatic benefits. Some clinicians find it beneficial to reduce levodopainduced dyskinesias in advanced PD. Disadvantages include amantadine s potential for development of tolerance, neuropsychiatric/cognitive side effects, ankle edema, and livedo reticularis (skin mottling). 1,8 Selegiline Selegiline is a selective MAO type B inhibitor that has mild symptomatic benefit in early PD, but is primarily used as an adjunct to levodopa in advanced patients with motor fluctuations. The major side effects include nausea, insomnia, hallucinations, and worsening of levodopa-related dyskinesias. Recent evidence does not support a neuroprotective effect for selegiline. 1,8 Dopamine agonists In the United States, two ergot-derived DAs (bromocriptine pergolide) have been used for many years to treat PD and recently two non ergot-derived DAs (pramipexole ropinirole) have been introduced. 1 Compared with levodopa, DAs do not require any metabolic steps to provide a therapeutic effect, they do not compete with plasma amino acids for transport across the blood-brain Table 1. Differential Diagnosis of Parkinson s Disease. Neurodegenerative Hereditary Disorders Disorders with Associated with Other Symptomatic Parkinsonian Features Parkinsonism Disorders Drug-induced Progessive supranuclear palsy Wilson s disease Essential tremor Toxin-induced Multiple system atrophy Huntington s disease Psychogenic Vascular Alzheimer s disease Dentatorubral-pallidoluysian atrophy Structural lesions Diffuse Lewy Machado-Joseph body disease disease Hydrocephalus Infections Metabolic Posttraumatic With permission. Corticobasal degeneration barrier and they have a longer half-life. Dopamine agonists are effective for the treatment of tremor, bradykinesia, and rigidity. Dopaminergic agonists were originally approved for use as adjuncts to levodopa in patients with advanced PD who experience motor complications. More recently, they have been shown to be quite effective as monotherapy in the treatment of early PD. Levodopa may then supplement DA therapy to enhance symptom control. Side effects associated with DAs include EDS and sleep attacks. These unintended sleep episodes are associated with all dopaminergic agents, including levodopa. Other adverse effects include hypotension, hallucinations or psychosis, nausea and vomiting, and edema of the legs. Dopaminergic agonists may rarely cause dyskinesias as monotherapy but can do so when added to levodopa treatment. Levodopa/carbidopa Levodopa/carbidopa, the most effective medication for treating PD motor symptoms, has been the cornerstone of PD pharmacotherapy for the past 30 years. Morbidity and mortality due to PD have been reduced by the use of levodopa, and virtually all patients with confirmed, idiopathic PD will eventually be treated with levodopa with clinically significant benefit. Levodopa may be used throughout the course of PD. Since dopamine cannot cross the blood-brain barrier, its precursor, levodopa, is used. Levodopa has a short elimination half-life and, when used alone, is converted to dopamine in the periphery. This produces nausea and vomiting and reduces the amount of levodopa that can penetrate the blood-brain barrier. The decarboxylase inhibitor carbidopa prevents peripheral levodopa metabolism and enhances CNS absorption. As with all PD medications, levodopa dose should be started low and gradually increased to minimize acute side effects. The lowest dose of levodopa that provides a satisfactory clinical response should be used. Despite its benefits, significant adverse events are associated with levodopa treatment. Acutely, patients may develop nausea, vomiting, lightheadedness, and hallucinations. Of most concern is the development of motor fluctuations and dyskinesias (see below). As PD progresses, the response to treatment with levodopa often begins 3
4 to fluctuate, becoming increasingly correlated with fluctuations in plasma concentrations. 1,7 COMT-inhibitors Catechol-O-methyltransferase (COMT) inhibitors (tolcapone, entacapone) inhibit peripheral metabolism of levodopa, thereby extending its half-life and increasing CNS absorption. Using levodopa with a COMT inhibitor decreases the variability in levodopa concentrations and reduces motor fluctuations. This has the clinical benefit of decreased off time and increased on time for patients with motor fluctuations. Dyskinesia is the most common side effect, and may be controlled by a 15% to 30% reduction in levodopa dose. Other side effects are diarrhea, abdominal cramps, and pain. Because of the risk for liver toxicity, tolcapone s use has been severely restricted, and entacapone is preferred. 1,8,9 Motor Fluctuations and Dyskinesias Many patients eventually notice that their 4 Early 3 5 hours Moderate hours Advanced Figure 2. Motor fluctuations and dyskinesias related to levodopa therapy. With permission of Lippincott Williams and Wilkins. motor response to oral medications begins to fluctuate and dyskinesias appear. This phenomenon rises from 3% after 12 months of treatment to 70% after more than 9 years. 10 Motor complications and dyskinesia may be related to changes in the firing frequency of basal ganglia output neurons and effects of these changes on thalamic and cortical motor areas. Motor fluctuations consist of alternations between on periods during which patients have relatively good mobility and motor function, and off periods during which the patients have suboptimal or no response to medication. Several types of motor fluctuations may develop as the disease progresses, including end-of-dose wearing off, delayed on response, dose failures, and unpredictable responses. Dyskinesias usually begin as a twisting, posturing, or cramping of the toes or feet on awakening ( off state dystonia) or as a choreiform disorder of the side of the body most affected by PD ( on state dyskinesia). Patients with dyskinesias usually are those who are very responsive to dopaminergic medications. Peak-dose dyskinesia associated with PD usually begins after the dose of dopaminergic medication has been absorbed and brain/blood levels have peaked. As PD progresses, the therapeutic window for eliciting a motor response to References medication without causing a dyskinetic response is compressed (Fig. 2). 11 Carefully titrating the dose of the dopaminergic medication, discontinuing selegiline or COMT inhibitors, adding amantadine, or surgery in extreme cases may be useful. 7,8,12 Surgery Surgical options for PD generally fall within three categories: ablative, stimulating, and restorative. Pallidotomy, an ablative procedure, results in a consistent, long-lasting, and dramatic amelioration of contralateral dyskinesia in 90% of patients. Deep brain stimulation is based on observations indicating that high-frequency stimulation of specific brain sites can simulate the effects of a destructive lesion. Deep brain stimulation of the subthalamic nucleus and the globus pallidus pars interna both provide comparable benefits, including management of tremor. Restorative procedures, such as fetal cell transplants, are still in the experimental stages. Conclusion Patients with PD present with a constellation of clinical symptoms that change as the disease progresses. Optimal management must include accurate diagnosis, recognition of the wide variety of complex treatment issues, and choice of the best therapeutic options individualized for each patient. Treatment goals should focus on symptom control and improved quality of life. TX 1. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson s disease (2001): treatment guidelines. Neurology. 2001;56(suppl 5):S1-S Lang AE, Lozano AM. Parkinson s disease. First of two parts. N Engl J Med. 1998;339: Guttman M, Kish SJ, Furukawa Y. Current concepts in the diagnosis and management of PD. CMAJ. 2003;168: Marjama-Lyons JM and Koller WC. Parkinson s disease: update in diagnosis and symptom management. Geriatrics. 2001;56: Adler CH. Differential diagnosis of Parkinson s disease. Med Clin N Am. 1999;83: Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55: Jankovic JJ. Therapeutic strategies in Parkinson s disease. In: Jankovic JJ, Tolosa E, eds. Parkinson s Disease and Movement Disorders. 4th Edition. Philadelphia, Pa: Lippincott Williams and Wilkins; Chapter Uitti RJ. Advancing Parkinson s disease and treatment of motor complications. In: Adler CH, Ahlskog JE, eds. Parkinson s Disease and Movement Disorders: Diagnosis and Treatment Guidelines for the Practicing Physician. Totowa, New Jersey: Humana Press; Chapter Kurth MC, Adler CH. COMT inhibition: a new treatment strategy for Parkinson s disease. Neurology. 1998;50(5 suppl 5):S Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations estimated from the cumulative literature. Mov Disord. 2001;16: Obeso JA et al. Dopamine agonists in early Parkinson s Disease. In: Olanow CW, Obeso JA, eds. Beyond the Decade of the Brain Vol 2. Kent, UK: Wells Medical Ltd; 1997: Adler CH. Relevance of motor complications in Parkinson s disease. Neurology. 2002;58:S
5 CME Posttest Part 1 of 6: Overview of Parkinson s Disease CME Instructions Awake & Involved: Addressing Excessive Daytime Sleepiness in Patients with Parkinson s Disease To receive documentation of your participation in this six-part CME activity (for which each newsletter equals.50 hours of CME credit) for a total of 3.0 hours of CME credit, please complete the following steps: 1. Read each newsletter carefully. 2. Complete the CME Posttest included in each of the newsletters. 3. Mail or fax each of your completed CME Posttests to Projects In Knowledge, One Harmon Plaza, 6th Floor, Secaucus, NJ 07094; fax: * *Successful completion for 3.0 hours of CME credit requires a passing score of 70% or higher on each of the 6 posttests. After you have submitted all 6 posttests, you will be issued a CME certificate for 3.0 hours of CME credit. If your score is lower than 70% on any individual posttest, you will be notified by mail and given an opportunity to retake that test. Name Degrees/Credentials Mailing Address City State ZIP Phone Office Fax Please indicate your answers below. 1. The best predictors of a pathologic diagnosis of PD do not include: a. Unilateral onset of symptoms c. Bilateral onset of symptoms b. Good initial response to levodopa d. Bradykinesia 2. Selegiline should not be used: a. For patients with early PD c. For its neuroprotective effect b. As an adjunct to levodopa in advanced PD patients d. For patients with motor fluctuations 3. Unlike dopamine agonists, levodopa is not associated with sleep attacks. a. True b. False 4. Treatment options for a patient with peak-dose dyskinesia should not include: a. Titrating the dose of dopaminergic medication c. Raising the dose of entacapone b. Discontinuing selegiline d. Pallidotomy Thank you for your participation PT
What is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician
What is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician Overview of presentation Case history Video example pre and post treatment Historical review PD in the UK Epidemiology and aetiology Making
More informationParkinson s Disease - A Junior Doctor s Survival Guide
Parkinson s Disease - A Junior Doctor s Survival Guide Professor Richard Walker Consultant Geriatrician Hon. Professor of Ageing & Interna
More informationManagement of Parkinson s Disease in Primary Care
Management of Parkinson s Disease in Primary Care Dr June Tan National University Hospital System (NUHS) Division of Neurology Senior Consultant Topics: Diagnosing PD Choice of medication in the de novo
More informationAnti-Parkinsonism Drugs
Anti-Parkinsonism Drugs Pharma Team 429 Fahad Alrumaih Ibrahim Alshiddi Sultan Alsalem Ismail Raslan Suhail Asiri Parkinsonism - Could be: primary [idiopathic] or secondary [viral infection or drug induced
More informationDementia & Movement Disorders
Dementia & Movement Disorders A/Prof Michael Davis Geriatrician ACT Health & GSAHS ANU Medical School Eastern Dementia Network Aged and Dementia Care Symposium Bateman s Bay, 22 October 2010 Types of Dementia
More informationUnderstanding Parkinson s Disease
Understanding Parkinson s Disease Irene Oh, MD Neurologist, Movement Disorders Specialist The Neurology Center of Southern California, Encinitas & Escondido Introduction PD was first described in 1817
More informationParkinson's s disease - a
Parkinson's Disease Parkinson's s disease - a progressive disorder of the nervous system that affects movement. The most common perception of Parkinson s is the patient having tremors. Hands shaking, inability
More informationPARKINSON S DISEASE AND PARKINSONISM. Dr Phil Wood Geriatrician, Waitemata DHB Clinical Unit Leader, Waikato DHB
PARKINSON S DISEASE AND PARKINSONISM Dr Phil Wood Geriatrician, Waitemata DHB Clinical Unit Leader, Waikato DHB OUTLINE Covering:- Why this is an important area of Medical and Psychiatric care The variety
More informationChapter 28. Drug Treatment of Parkinson s Disease
Chapter 28 Drug Treatment of Parkinson s Disease 1. Introduction Parkinsonism Tremors hands and head develop involuntary movements when at rest; pin rolling sign (finger and thumb) Muscle rigidity arthritis
More informationParkinson s Disease and Tremors
Parkinson s Disease and Tremors Current Strategies Leah Karliner, MD, MAS Division of General Internal Medicine Disclosures I have no conflicts of interest Parkinsonism neurological syndrome: Bradykinesia:
More informationParkinson s disease. 14 June 2012
Parkinson s disease 14 June 2012 Cardinal sign of parkinsonism As least 2/4 for diagnosis Resting tremor Bradykinesia Rigidity Postural instability Classification Idiopathic Parkinson disease Secondary
More informationCENTRAL NERVOUS SYSTEM MANAGEMENT OF PARKINSON S DISEASE
MANAGEMENT CENTRAL NERVOUS SYSTEM MANAGEMENT OF PARKINSON S DISEASE Parkinson s Disease is classically determined by the triad or rest tremor (usually starting in one arm) with bradykinesia (slowing of
More informationMr James Garrard University of Leicester May 2014
Parkinson s disease exemplifies the art and science of geriatric medicine. Introduction First described by Dr. James Parkinson in the classic essay The Shaking Palsy in 1817 (1), Parkinson s disease is
More informationGLOSSARY OF TERMS. This glossary explains the terms and words often used in association with Parkinson s.
Antagonist This glossary explains the terms and words often used in association with Parkinson s. Medications which have a negative effect on particular cells in the body. In Parkinson s dopamine antagonists
More informationNeuropharmacology I Parkinson s Disease and Movement Disorders
Harvard-MIT Division of Health Sciences and Technology HST.151: Principles of Pharmocology Instructor: Dr. David Standaert Standaert 1 Neuropharmacology I Parkinson s Disease and Movement Disorders What
More informationDoncaster & Bassetlaw Medicines Formulary
Doncaster & Bassetlaw Medicines Formulary Section 4.9: Drugs Used in Parkinsonism and related Disorders Co-Beneldopa 12.5/50, 25/100 and 50/200 (Madopar) Capsules Co-Beneldopa 12.5/50 and 25/100 Dispersible
More informationThe majority of parkinsonism (approx. 80%) is due to idiopathic PD other causes include drug therapy (Table 1),toxins and trauma.
THE TREATMENT OF PARKINSON S DISEASE SUMMARY Levodopa (L-dopa) administered in conjunction with a dopa decarboxylase inhibitor (DDCI) remains the mainstay of therapy for Parkinson s disease. New drugs
More informationClinical Psychopharmacology
Clinical Psychopharmacology Antiparkinsonian drugs Department of Pharmacy, GGZ WNB Chair on Pharmacotherapy in Psychiatric Patients/Anton Loonen May 2015 2 Basal ganglia diseases Parkinson s disease and
More informationHow To Treat Aphasic Depression
Antipsychotic Use in Patients with Parkinson s Disease 단국의대 정신과 이석범 Difficulties in Parkinson's disease Motor symptoms Neuropsychiatric syndromes Severe Disability Cognitive impairment 2 Neuropsychiatric
More informationPARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS
PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS De Anna Looper, RN CHPN Corporate Clinical Consultant / Legal Nurse Consultant Carrefour Associates L.L.C. PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS
More informationNursing Care of Patients with Movement Disorders. Catholic Health 2 nd Annual Neurorehab Symposium November 1, 2014
Nursing Care of Patients with Movement Disorders Catholic Health 2 nd Annual Neurorehab Symposium November 1, 2014 Types of Movement Disorders Parkinson s disease Huntington s disease Dystonia Tremors
More informationMotor Fluctuations in Parkinson s
Motor Fluctuations in Parkinson s What are motor fluctuations? Motor fluctuations are associated with longterm use of levodopa (trade names Sinemet or Madopar, Co-careldopa or Co-beneldopa), and usually
More informationEmergency Room Treatment of Psychosis
OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different
More informationSLEEP AND PARKINSON S DISEASE
A Practical Guide on SLEEP AND PARKINSON S DISEASE MICHAELJFOX.ORG Introduction Many people with Parkinson s disease (PD) have trouble falling asleep or staying asleep at night. Some sleep problems are
More informationDiagnosing Parkinson s disease (PD) in
MedicineToday 2015; 16(1): 12-18 PEER REVIEWED FEATURE 2 CPD POINTS The clinical challenge of early Parkinson s disease SIMON J.G. LEWIS MB BCh, BSc, MRCP, FRACP, MD Early Parkinson s disease may be challenging
More informationUnmet Needs for Parkinson s Disease Therapeutics
Unmet Needs for Parkinson s Disease Therapeutics Coalition Against Major Diseases & FDA Workshop October 20, 2014 Caroline M Tanner MD, PhD Director, Parkinson's Disease Research Education and Clinical
More informationParkinson s Disease: General Information
Parkinson s Disease: General Information Does PD come in stages? If so, how many stages? Hubert Fernandez, MD: Staging provides an artificial classification of a patient's illness severity but, in reality,
More informationPARKINSON S DISEASE INTRODUCTION. Parkinson s disease is defined as a disease of the nervous system that affects voluntary movement.
PARKINSON S DISEASE INTRODUCTION Parkinson s disease is a disorder of the brain and the nervous system. It is one of the more common neurological diseases in people over the age of 60, and it is more common
More informationClinical Research in Parkinson s Disease: The Advances, Challenges, and Importance of Rater Training
Clinical Research in Parkinson s Disease: The Advances, Challenges, and Importance of Rater Training Marian A. Ormont, MD epharmasolutions, A WIRB-Copernicus Group Company April is Parkinson s disease
More informationDiagnosis and Treatment of Parkinson s Disease: A Systematic Review of the Literature
Evidence Report/Technology Assessment Number 57 Diagnosis and Treatment of Parkinson s Disease: A Systematic Review of the Literature Prepared for: Agency for Healthcare Research and Quality U.S. Department
More informationSLEEP DIFFICULTIES AND PARKINSON S DISEASE Julie H. Carter, R.N., M.S., A.N.P.
SLEEP DIFFICULTIES AND PARKINSON S DISEASE Julie H. Carter, R.N., M.S., A.N.P. Problems with sleep are common in Parkinson s disease. They can sometimes interfere with quality of life. It is helpful to
More informationParkinson Disease Levodopa-Induced Dyskinesia. Christopher Kenney, MD Novartis Pharmaceuticals
Parkinson Disease Levodopa-Induced Dyskinesia Christopher Kenney, MD Novartis Pharmaceuticals Disclosures Dr. Kenney is a full-time employee of Novartis Pharmaceuticals Corporation The opinions expressed
More informationDisordered sleep at night has long been
Neurology 59 Excessive daytime sleepiness in PD Excessive Daytime Sleepiness (EDS) in Parkinson s disease (PD) is an important issue that warrants serious attention because it can have adverse effects
More informationRecognition and Treatment of Depression in Parkinson s Disease
Recognition and Treatment of Depression in Parkinson s Disease Web Ross VA Pacific Islands Health Care System What is depression? Depression is a serious medical condition that affects a person s feelings,
More informationParkinson s Disease and Dementia. Dr N Samaniego Consultant Physician and Geriatrician
Parkinson s Disease and Dementia Dr N Samaniego Consultant Physician and Geriatrician Case 68 year old female. Off legs for a few months, O/E no neurological deficit. -Slowing down -Needs help with dressing,
More informationABC s of Parkinson s Disease 4/29/15 Karen Parenti, MS, PsyD
ABC s of Parkinson s Disease 4/29/15 Karen Parenti, MS, PsyD What is Parkinson s Disease? Parkinson's disease is a progressive disorder of the nervous system that affects movement. It develops gradually,
More informationMotor dysfunction 2: Spinal cord injury and subcortical motor disorders ANATOMY REVIEW: Basal Ganglia
Motor dysfunction 2: Spinal cord injury and subcortical motor disorders ANATOMY REVIEW: Basal Ganglia A group of subcortical nuclei caudate, putamen, globus pallidus Caudate & Putamen = Neostriatum caudate
More informationMOTION AND E-MOTION. Andrea Cavanna MD PhD FRCP
MOTION AND E-MOTION Andrea Cavanna MD PhD FRCP Consultant in Behavioural Neurology, BSMHFT, Birmingham, UK Hon Professor in Neuropsychiatry, Aston University, Birmingham, UK Hon Reader in Neuropsychiatry,
More informationTreatments for Major Depression. Drug Treatments The two (2) classes of drugs that are typical antidepressants are:
Treatments for Major Depression Drug Treatments The two (2) classes of drugs that are typical antidepressants are: 1. 2. These 2 classes of drugs increase the amount of monoamine neurotransmitters through
More informationManagement of Parkinson s disease and co-existent health problems is a long journey, requiring a multidisciplinary team approach.
Diagnosis and management of Parkinson s Disease Key points 1. 2. 3. 4. 5. 6. The diagnosis of Parkinson s disease is still based on careful history taking and clinical examination, despite ongoing advances
More informationLevels of evidence and grades of recommendation
MOH Clinical Practice Guidelines 6/2007 Levels of evidence and grades of recommendation Levels of Evidence Level Type of Evidence 1 ++ High quality meta analyses, systematic reviews of RCTs, or RCTs with
More informationParkinson's disease. Definition. Symptoms
Parkinson's disease Definition Parkinson's disease is a progressive disorder of the nervous system that affects your movement. It develops gradually, sometimes starting with a barely noticeable tremor
More informationChad Christine, MD UCSF
Parkinsonism: Clinical Features and Treatments Parkinson's disease is a condition whose main features are slowed movement, tremor, and gait or balance problems. More than1 million people in the United
More informationDisorders Considered. A Brief Synopsis of Select Neurological Disorders. Neurological and Psychiatric Symptoms. Neurological Basis
Disorders Considered A Brief Synopsis of Select Neurological Disorders Four neurological disorders are examined to illustrate pathological conditions that can develop related to course material Myasthenia
More informationDEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE
1 DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE ASSESSMENT/PROBLEM RECOGNITION 1. Did the staff and physician seek and document risk factors for depression and any history of depression? 2. Did staff
More informationIII./3.1.2. Parkinsonian syndrome (parkinsonism, atypical parkinsonian disorders) in neurodegenerative diseases
III./3.1.2. Parkinsonian syndrome (parkinsonism, atypical parkinsonian disorders) in neurodegenerative diseases III./3.1.2.1. Multiple System Atrophy (MSA) MSA is a sporadic, adult onset degenerative neurological
More informationHow To Treat An Elderly Patient
1. Introduction/ Getting to know our Seniors a. Identify common concepts and key terms used when discussing geriatrics b. Distinguish between different venues of senior residence c. Advocate the necessity
More informationPharmacological Management of Parkinson s Disease Robert Iansek
GERIATRIC THERAPEUTICS Editors: Associate Professor Michael Woodward, Director, Aged and Residential Care Services, Dr Margaret Bird, Consultant Geriatrician, Mr Rohan Elliott, Clinical Pharmacist, Austin
More informationUpdate on Treatment of the Dementias
Update on Treatment of the Dementias Mark Pippenger, MD Behavioral Neurology Associate Clinical Professor of Neurology University of Arkansas for Medical Sciences Disclosures I will be discussing off-label
More informationAn Evidence-Based Approach to Management of Early Parkinson s Disease
Outcomes-Based Practice Series Editor: Bryan A. Liang, MD, PhD, JD An Evidence-Based Approach to Management of Early Parkinson s Disease Case Study and Commentary: Andrew Siderowf, MD, Heather J. Cianci,
More informationEBM Parkinson s Diseases
Parkinson s Diseases Version 1 Final Page 1 Document control Version history Version Date Comments 1e (draft) 30 March 2007 Comments from customer incorporated 1d (draft) 22 January 2007 Formatting 1c
More informationParkinson s Disease Symptoms Guide
Parkinson s Disease Symptoms Guide Some symptoms of Parkinson s disease (PD) are hard for even specialists to detect. Others are obvious even to an untrained eye. Parkinson s symptoms are different for
More informationMultiple System Atrophy guide (http://www.msaweb.co.uk/msaguide.htm)
Multiple System Atrophy guide (http://www.msaweb.co.uk/msaguide.htm) Accessing information on Multiple System Atrophy (MSA) can be hard work. The Sarah Matheson Trust (SMT) produces a guide to MSA that
More informationPARKINSON'S DISEASE The Disorder and Current Therapy Copyright 2008, Daniel Kassicieh, D.O.
PARKINSON'S DISEASE The Disorder and Current Therapy Copyright 2008, Daniel Kassicieh, D.O. Parkinson's disease is a common neurologic disorder. It affects people of all ages and ethnic backgrounds and
More informationSleep Difficulties. Insomnia. By Thomas Freedom, MD and Johan Samanta, MD
Sleep Difficulties By Thomas Freedom, MD and Johan Samanta, MD For most people, night is a time of rest and renewal; however, for many people with Parkinson s disease nighttime is a struggle to get the
More informationCholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW
Cholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW Diagnosis of Dementia : DSM-IV criteria Loss of memory and one or more other cognitive abilities Aphasia Apraxia Agnosia
More informationAn Introduction to Lewy Body Dementia
An Introduction to Lewy Body Dementia A special publication for people newly diagnosed with Lewy body dementia and those still seeking answers. You don t have to face LBD alone. Increasing Knowledge Sharing
More informationThe Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences
The Nuts and Bolts of Multiple Sclerosis Rebecca Milholland, M.D., Ph.D. Center for Neurosciences Objectives Discuss which patients are at risk for Multiple Sclerosis Discuss the diagnostic criteria for
More informationNEUROIMAGING in Parkinsonian Syndromes
NEUROIMAGING in Parkinsonian Syndromes (Focus on Structural Techniques: CT and MRI) Dr. Roberto Cilia Parkinson Institute, ICP, Milan, Italy OUTLINE Primary Parkinsonism Idiopathic Parkinson s Disease
More informationPARKINSONISM. akinetic-rigid syndrome
PARKINSONISM PARKINSONISM akinetic-rigid syndrome PARKINSONISM Symptoms of Parkinson s disease: akinesia, bradykinesia, rigidity, postural instability, gait impairment, tremor A common, age-related syndrome
More informationParkinson s prevalence in the United Kingdom (2009)
Parkinson s prevalence in the United Kingdom (2009) Contents Summary 3 Background 5 Methods 6 Study population 6 Data analysis 7 Results 7 Parkinson's prevalence 7 Parkinson's prevalence among males and
More informationParkinson s Disease (PD)
Parkinson s Disease (PD) Parkinson s disease (PD) is a movement disorder that worsens over time. About 1 in 100 people older than 60 has Parkinson s. The exact cause of PD is still not known, but research
More informationParkinson s disease (PD) is a progressive neurodegenerative
n reports n Advanced Strategies for Treatment of Parkinson s Disease: The Role of Early Treatment Michael W. Jann, PharmD Parkinson s disease (PD) is a progressive neurodegenerative disease associated
More informationWelcome to the Medical Risk Webinar: a taster of Assessing and Managing Medical Risk for Insurers courses. 26 April 2013
Welcome to the Medical Risk Webinar: a taster of Assessing and Managing Medical Risk for Insurers courses 26 April 2013 1 Parkinson s Disease & Multiple Sclerosis Dr Nick Niven Jenkins 2 Movement Human
More informationAlcohol Overuse and Abuse
Alcohol Overuse and Abuse ACLI Medical Section CME Meeting February 23, 2015 Daniel Z. Lieberman, MD Professor and Vice Chair Department of Psychiatry George Washington University Alcohol OVERVIEW Definitions
More informationJournal Club. Parkinsonismo iatrogeno
PROGETTO UNIVA 2013 Journal Club Parkinsonismo iatrogeno Pietro Gareri, MD, PhD Geriatra ASP Catanzaro Lamezia Terme 3 Luglio 2013 Drug-induced parkinsonism (DIP) was recognized in the early 1950s as a
More informationSIGN. Diagnosis and pharmacological management of Parkinson s disease. January 2010. A national clinical guideline
SIGN Scottish Intercollegiate Guidelines Network Part of NHS Quality Improvement Scotland Help us to improve SIGN guidelines - click here to complete our survey 113 Diagnosis and pharmacological management
More informationManagement in the pre-hospital setting
Management in the pre-hospital setting Inflammation of the joints Two main types: Osteoarthritis - cartilage loss from wear and tear Rheumatoid arthritis - autoimmune disorder Affects all age groups,
More informationDepression in Older Persons
Depression in Older Persons How common is depression in later life? Depression affects more than 6.5 million of the 35 million Americans aged 65 or older. Most people in this stage of life with depression
More informationA PALLIATIVE CARE APPROACH TO PARKINSON S AND OTHER NEURODEGENERATIVE DISEASES
National Hospice and Palliative Care Organization Palliative Care Resource Series A PALLIATIVE CARE APPROACH TO PARKINSON S AND OTHER NEURODEGENERATIVE DISEASES Mara Lugassy, MD Hospice Medical Director,
More informationLewy body dementia Referral for a Diagnosis
THE Lewy Body society The more people who know, the fewer people who suffer Lewy body dementia Referral for a Diagnosis Lewy Body Dementias REFERRAL FOR A DIAGNOSIS In the UK people with all forms of dementia
More informationA GUIDE FOR THE NEW PATIENT. supported by the Neurological Foundation
PARKINSON S A GUIDE FOR THE NEW PATIENT supported by the Neurological Foundation INTRODUCTION 1 Contents 1. Introduction 2. Parkinson s 3. The main symptoms of Parkinson s 6. What causes Parkinson s? 7.
More informationPrimary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment
Primary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment Kinga Szigeti, MD Associate Professor UBMD Neurology UB Department of Neurology Questions How do we differentiate
More informationMental health issues in the elderly. January 28th 2008 Presented by Éric R. Thériault etheriau@lakeheadu.ca
Mental health issues in the elderly January 28th 2008 Presented by Éric R. Thériault etheriau@lakeheadu.ca Cognitive Disorders Outline Dementia (294.xx) Dementia of the Alzheimer's Type (early and late
More informationAdvances in MOvEMEnt DIsOrDErs:
Advances in MOvEMEnt DIsOrDErs: The NYC Movement Disorder CME Symposium sunday, April 7, 2013 Icahn School of Medicine at Mount Sinai the goldwurm AuDItOrIuM New York, NY Course Director Course Co-Director
More informationSUMMARY OF RECOMMENDATIONS
SUMMARY OF RECOMMENDATIONS FOR THE LONG- TERM TREATMENT OF RLS/WED from AN IRLSSG TASK FORCE Members of the Task Force Diego Garcia- Borreguero, MD, Madrid, Spain* Richard Allen, PhD, Baltimore, MD, USA*
More informationParkinson s Disease Medications
Parkinson s Disease Medications By David Houghton, MD, MPH, Howard Hurtig, MD, and Sharon Metz, RN, MPH, with guest author Melanie Brandabur, MD Table of Contents Chapter 1 Introduction to Parkinson s
More informationMEDICATIONS AND PARKINSON'S DISEASE Cathi A.Thomas R.N., M.S.
MEDICATIONS AND PARKINSON'S DISEASE Cathi A.Thomas R.N., M.S. Medications to relieve or decrease symptoms of Parkinson s disease are an important and necessary part of care. For some people this may be
More informationMeeting the Needs of Aging Persons. Aging in Individuals with a
Meeting the Needs of Aging Persons with Developmental Disabilities Cross Network Collaboration for Florida Aging in Individuals with a Developmental Disability Module 3 Based on ADRC training developed
More informationParkinson s Disease: Factsheet
Parkinson s Disease: Factsheet Tower Hamlets Joint Strategic Needs Assessment 2010-2011 Executive Summary Parkinson s disease (PD) is a progressive neuro-degenerative condition that affects a person s
More informationUNIFIED PARKINSON'S DISEASE RATING SCALE
UNIFIED PARKINSON'S DISEASE RATING SCALE I. MENTATION, BEHAVIOR AND MOOD 1. Intellectual Impairment ne. 1 = Mild. Consistent forgetfulness with partial recollection of events and no other difficulties.
More informationGUIDELINES FOR USE OF PSYCHOTHERAPEUTIC MEDICATIONS IN OLDER ADULTS
GUIDELINES GUIDELINES FOR USE OF PSYCHOTHERAPEUTIC MEDICATIONS IN OLDER ADULTS Preamble The American Society of Consultant Pharmacists has developed these guidelines for use of psychotherapeutic medications
More informationPreliminary Investigation of Risk Factors Causing Dyskinesias in Parkinson s Disease in South Africa
Tropical Journal of Pharmaceutical Research August 2014; 13 (8): 1353-1359 ISSN: 1596-5996 (print); 1596-9827 (electronic) Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001
More informationSinemet (Parkinson's Disease) - Forecast and Market Analysis to 2022
Brochure More information from http://www.researchandmarkets.com/reports/2834728/ Sinemet (Parkinson's Disease) - Forecast and Market Analysis to 2022 Description: Sinemet (Parkinson s Disease) - Forecast
More informationMULTIMODAL THERAPY FOR MS- ASSOCIATED COGNITIVE DYSFUNCTION
MULTIMODAL THERAPY FOR MS- ASSOCIATED COGNITIVE DYSFUNCTION Michael K. Racke, MD Professor and Chairman in Neurology The Helen C. Kurtz Chair in Neurology Department of Neurology Ohio State University
More informationParkinson s Disease. Challenges, Progress and Hope
Parkinson s Disease Challenges, Progress and Hope Parkinson s Disease: Challenges, Progress and Hope Course #226 5 Contact Hours Author: Ellen Steinbart, RN, MA Course Material valid through 09/2016 Copyright
More informationSLEEP DISTURBANCE AND PSYCHIATRIC DISORDERS
E-Resource December, 2013 SLEEP DISTURBANCE AND PSYCHIATRIC DISORDERS Between 10-18% of adults in the general population and up to 50% of adults in the primary care setting have difficulty sleeping. Sleep
More informationProgress in MS: Current and Emerging Therapies
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC The MS Society gratefully acknowledges the grant received from Biogen Idec Canada, which makes possible the
More informationDepression is a common biological brain disorder and occurs in 7-12% of all individuals over
Depression is a common biological brain disorder and occurs in 7-12% of all individuals over the age of 65. Specific groups have a much higher rate of depression including the seriously medically ill (20-40%),
More informationPersonal Health Record
Personal Health Record Contents Section 1: Personal details (pages 4 6) Within this section you can note all information about you, next of kin, important health information and general medical history.
More informationParkinson s Disease: A Review of Motor and Nonmotor Symptoms
Diana Hong Parkinson s Disease: A Review of Motor and Nonmotor Symptoms Abstract: Although Parkinson s disease (PD) is considered a motor system disorder caused by the degeneration of dopaminergic neurons
More informationNEW PATIENT CLINICAL INFORMATION FORM. Booth Gardner Parkinson s Care & Movement Disorders Center Evergreen Neuroscience Institute
NEW PATIENT CLINICAL INFORMATION FORM Booth Gardner Parkinson s Care & Movement Disorders Center Evergreen Neuroscience Institute Date: Name: Referring Doctor: How did you hear about us? NWPF Your Physician:
More information2014 Alzheimer s Disease Facts and Figures
2014 Alzheimer s Disease Facts and Figures Includes a Special Report on Women and Alzheimer s Disease Almost two-thirds of Americans with Alzheimer s disease are women. Alzheimer s Disease is the six eading
More informationCurrent evidence suggests that Parkinson s tends to develop
About Parkinson's Diagnosing Parkinson s Current evidence suggests that Parkinson s tends to develop gradually and it may be many months, even years, before the symptoms become obvious enough for you to
More informationThese guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes.
This is a new guideline. These guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes. It incorporates NICE clinical
More informationMovement Disorders and Extrapyramidal System. Doç.. Dr. Sibel Ertan
Movement Disorders and Extrapyramidal System Doç.. Dr. Sibel Ertan İ.Ü.. CTF. Nöroloji N ABD. Motor System I. neuron (corticospinal pathway) Extrapyramidal system (basal ganglia) Cerebellum Loops for praxis
More informationLong Term Care Formulary HCD - 09. Anti-Dementia Drugs (e.g. donepezil, galantamine, rivastigmine, memantine)
1 of 8 USE OF CHOLINESTERASE (AChE) INHIBITORS The cholinesterase inhibitor anti-dementia drugs are indicated for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer s
More informationHow To Cover Occupational Therapy
Guidelines for Medical Necessity Determination for Occupational Therapy These Guidelines for Medical Necessity Determination (Guidelines) identify the clinical information MassHealth needs to determine
More informationPrevalence of Parkinsonism and its aetiological subtypes within patients with movement disorders
Research papers Prevalence of and its aetiological subtypes within patients with movement disorders D G S V D Gajasinghe* AL 2002 batch of students, Faculty of Medicine, University of Colombo Abstract
More informationREHABILITATION MEDICINE by PROFESSOR ANTHONY WARD
REHABILITATION MEDICINE by PROFESSOR ANTHONY WARD What is Rehabilitation Medicine? Rehabilitation Medicine (RM) is the medical specialty with rehabilitation as its primary strategy. It provides services
More information